Press Releases

Press Releases

WAVE Life Sciences Ltd., a genetic medicines company focused on developing stereopure nucleic acid therapies for patients impacted by rare diseases, today announced that it has been added to the Russell 2000®, Russell 3000®, Russell Microcap® and the Russell Global® Indexes following this year’s Russell Indexes Reconstitution, effective as of…

Press Releases

One of Australia's successful biotechnology scientists, Dr Graham Kelly, has announced the formation of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm is seeking to raise $6m in an IPO and to list on the ASX. Noxopharm is a clinic-ready company with its first anti-cancer…

Press Releases

Teva Pharmaceutical Industries Ltd. announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorization for CINQAERO® (reslizumab), a humanized interleukin 5 antagonist monoclonal antibody for add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite…

Press Releases

Protein Sciences Corporation announced today that FDA has extended the shelf life for Flublok, its game changing seasonal influenza vaccine, to 9 months from the date of manufacture- increasing the previous shelf life by 3 months.  The longer shelf life will make it easier for healthcare providers and pharmacies to…

Press Releases

Roche announced that it has received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing solution for people with severe sepsis or septic shock. With this clearance, Roche is the first IVD company in the U.S to provide a fully integrated solution for sepsis risk assessment…

Press Releases

FACIT has announced the creation of a new Ontario biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), to manage the development and commercialization of a portfolio of first-in-class WDR5 inhibitors for the treatment of various cancers. Epigenetic targets such as WDR5 represent an exciting class of therapies, possessing the…

Press Releases

Biocon Ltd., Asia's premier biopharmaceutical company, and Quark Pharmaceuticals, Inc., a leader in the discovery and development of novel RNA interference (RNAi)-based therapeutics, announced today the randomization of the first patient in India in the pivotal global Phase II/III study of QPI-1007, a novel siRNA (small interfering RNA) drug candidate…

Press Releases

Incyte Corporation today announced that the first patient has been treated in the ECHO-301 study—a Phase 3 trial evaluating epacadostat, Incyte’s investigational, highly potent and selective oral IDO1 inhibitor, in combination with Keytruda® (pembrolizumab), Merck’s anti-PD-1 therapy, as first-line treatment for patients with advanced or metastatic melanoma. Incyte expects initial…

Press Releases

Cerulean Pharma Inc., a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced the publication of preclinical proof of concept data for its lead compound, CRLX101, in the journal Cancer Research. The publication highlights that CRLX101 demonstrated strong antitumor activity, as monotherapy and in combination with Avastin® (bevacizumab), leading to complete…

Press Releases

Frontier Biotechnologies Inc. today reported that a Phase 2 clinical trial for its novel patch product AB001 met primary endpoint at week-2, demonstrating statistically significant (p=0.023) and clinically meaningful pain relief against placebo. Conducted at nine clinical centers in the United States, the trial enrolled 146 patients with chronic low…